ArticleMolecular biotechnology2026
Integrative Analysis of the Role of MRPL21 in Human Pan-Cancer and Its Relationship with the Progression of Lung Adenocarcinoma.
Article in Molecular biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrated single-cell and transcriptomic analysis of bone marrow-derived metastatic neuroblastoma reveals molecular mechanisms of metabolic reprogramming.Scientific reports · 2025Article
- MRPL21-PARP1 axis promotes cisplatin resistance in head and neck squamous cell carcinoma by inhibiting autophagy through the PI3K/AKT/mTOR signaling pathway.Journal of experimental & clinical cancer research : CR · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial ribosomal protein L21 (MRPL21) is essential for normal cell function and may play a significant role in cancer development. In this study, we performed a comprehensive pan-cancer analysis to explore MRPL21's function across different cancers, utilizing multiple online data platforms such as TCGA. Our analysis covered its clinical significance and biological functions, including expression levels, survival and diagnostic analysis, gene mutations, multidimensional immune-correlation analysis, tumor heterogeneity, and cancer-associated signaling pathways. Additionally, we constructed a prognostic nomogram for lung adenocarcinoma (LUAD) patients based on MRPL21 and validated its biological function through in vitro experiments. Our findings revealed that MRPL21 is commonly overexpressed in various cancers and is associated with poor prognosis. It significantly impacts cancer-related pathways, particularly those related to cell cycle activation. Moreover, MRPL21 is critical in the tumor microenvironment and is closely linked to immune infiltration across several cancer types. Its expression correlates with essential factors such as tumor mutational burden, microsatellite instability, immune checkpoint, and methylation patterns. In LUAD, MRPL21 was identified as an independent risk factor and demonstrated that MRPL21 promotes LUAD progression. Overall, MRPL21 holds potential as both a diagnostic and prognostic marker in cancer and could serve as a promising therapeutic target, particularly for LUAD.
Indexed as
Identifiers
39775548What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.